Screening and predication on tumor neoantigen for primary plasma cell leukemia
10.3872/j.issn.1007-385x.2019.07.002
- VernacularTitle:原发性浆细胞白血病肿瘤新生抗原的筛查和预测
- Author:
CHEN Biqing
;
KONG Xiangtu
;
XU Zuqiong
;
DAI Xingbin
;
YU Juhua
;
ZHU Xuejun
- Publication Type:Journal Article
- Keywords:
primary plasma cell leukemia;
neoantigen;
relapsed and refractory;
next generation sequencing;
somatic mutation;
immunotherapy
- From:
Chinese Journal of Cancer Biotherapy
2019;26(7):730-735
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the tumor-specific neoantigen for primary plasma cell leukemia (PCL) using gene sequencing technology combined with bioinformatic analysis. Methods: Peripheral blood samples of one patient with primary PCL during relapse and remission periods were collected. HLA molecular typing was performed using polymerase chain reaction with sequencing-based typing; whole-exome and transcriptome were sequenced by next-generation sequencing method; and bioinformatics software NetMHCpan was used to predict neoantigens. Results: Six tumor-specific missense mutations were found in the patient's peripheral blood during relapse period, located in genes FRG1, MLL3, SVIL, MYOM1, ZDHHC11 and RFPL4A.Considering patient's HLA sub-types, 43 neoantigens were predicted via bioinformatics. Considering that FRG1 and MLL3 had relatively high gene expression levels, 20 neoantigens derived from mutations of the two genes were preferentially selected, among which four neoantigens had high affinity with the patient's HLA molecules and thus had potential clinical application value. Conclusion: The study has completed a tumor neoantigen screen and prediction for primary PCL. This practice demonstrates that predicting neoantigen based on tumor-specific somatic mutation is feasible for primary PCL.
- Full text:20190702.pdf
